Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

GKOS

Glaukos Corporation

Nov 27 • 04:00PM ET

142.69

Dollar change +1.96
Percentage change 1.39	%

Healthcare • Medical Devices • USA • NYSE

Peers: ALGN ZBH BSX EW ISRG MDT SYK COO BAX HOLX

| Held by: IJR VTI IWM VB VXF VBK IJT SPSM IWO IHI

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.96	Insider Own	3.64%	Shs Outstand	55.14M	Perf Week	0.88%
Market Cap	7.98B	Forward P/E	-	EPS next Y	-1.09	Insider Trans	-2.49%	Shs Float	53.13M	Perf Month	3.59%
Income	-149.57M	PEG	-	EPS next Q	-0.37	Inst Own	99.78%	Short Float	5.29%	Perf Quarter	7.62%
Sales	360.35M	P/S	22.14	EPS this Y	19.70%	Inst Trans	1.06%	Short Ratio	5.30	Perf Half Y	28.90%
Book/sh	12.13	P/B	11.76	EPS next Y	40.14%	ROA	-15.95%	Short Interest	2.81M	Perf Year	138.81%
Cash/sh	4.69	P/C	30.39	EPS next 5Y	8.00%	ROE	-26.10%	52W Range	59.22 - 146.86	Perf YTD	79.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-49.95%	ROI	-18.12%	52W High	-2.84%	Beta	1.03
Dividend TTM	-	Quick Ratio	4.71	Sales past 5Y	12.76%	Gross Margin	78.14%	52W Low	140.95%	ATR (14)	4.69
Dividend Ex-Date	-	Current Ratio	5.54	EPS Y/Y TTM	-10.22%	Oper. Margin	-30.50%	RSI (14)	57.23	Volatility	2.96% 3.71%
Employees	907	Debt/Eq	0.24	Sales Y/Y TTM	18.70%	Profit Margin	-41.51%	Recom	1.73	Target Price	142.42
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	37.80%	Payout	-	Rel Volume	0.66	Prev Close	140.73
Sales Surprise	5.66%	EPS Surprise	41.40%	Sales Q/Q	23.86%	Earnings	Nov 04 AMC	Avg Volume	530.41K	Price	142.69
SMA20	2.44%	SMA50	6.82%	SMA200	23.68%	Trades		Volume	348,798	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Downgrade	Citigroup	Buy → Neutral	$132
May-06-24	Upgrade	Jefferies	Hold → Buy	$84 → $125
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight	$66 → $91
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$65
Nov-28-23	Initiated	Truist	Buy	$88
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$75 → $83
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight	$55 → $80
Dec-22-22	Initiated	Mizuho	Neutral	$48
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral	$48 → $42
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$57
Oct-14-22	Resumed	Stephens	Overweight	$69
Oct-04-22	Initiated	Needham	Buy	$66
Jul-12-22	Upgrade	Stifel	Hold → Buy	$40 → $60
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight	$56
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy	$61
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight	$68
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight	$70
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight	$41
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform

Show Previous Ratings

Nov-08-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Nov-06-24 06:30AM	Glaukos price target raised to $145 from $135 at Wells Fargo (TipRanks) +10.00%
Nov-05-24 11:30AM	Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
11:18AM	Q3 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ... (GuruFocus.com)
05:25PM	Loading…
Nov-04-24 05:25PM	Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Glaukos: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Third Quarter 2024 Financial Results (Business Wire)
Nov-01-24 09:01AM	Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result (GuruFocus.com)
Oct-28-24 10:01AM	Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-17-24 10:06AM	Glaukos eyes FDA approval for ocular therapy after Phase III win (Pharmaceutical Technology)
Oct-16-24 04:05PM	Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety (Business Wire)
Oct-14-24 07:00AM	Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-09-24 07:00AM	Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 (Business Wire)
Sep-09-24 05:16AM	Heres Why Glaukos (GKOS) Appreciated in Q2 (Insider Monkey)
02:16AM	Loading…
Sep-03-24 02:16AM	Better Than Expected Earnings Results Boosted Glaukos Corp (GKOS) in Q2 (Insider Monkey)
Aug-22-24 01:16PM	Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock? (Zacks)
Aug-16-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Aug-02-24 07:00PM	Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:50AM	Should You Be Bullish on Glaukos Corporation (GKOS)? (Insider Monkey)
Aug-01-24 11:40AM	Q2 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
07:31AM	Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales (Zacks)
Jul-31-24 09:57PM	GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:20PM	Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:16PM	Glaukos: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Second Quarter 2024 Financial Results (Business Wire)
Jul-24-24 10:01AM	Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-22-24 11:27AM	Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock? (Zacks)
Jul-10-24 07:00AM	Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31 (Business Wire)
Jul-03-24 07:38AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
12:49PM	Loading…
Jun-27-24 12:49PM	Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock? (Zacks)
03:19AM	Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar? (Zacks)
Jun-14-24 07:00AM	Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock (Business Wire)
Jun-05-24 12:14PM	Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally? (Zacks)
Jun-03-24 01:53PM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
May-28-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
May-14-24 04:47PM	Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing (MT Newswires)
12:20PM	Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock? (Zacks)
May-02-24 12:01PM	Needham Adjusts Price Target on Glaukos to $113 From $108, Maintains Buy Rating (MT Newswires) +6.19%
11:59AM	JPMorgan Adjusts Price Target on Glaukos to $110 From $108, Maintains Overweight Rating (MT Newswires)
09:14AM	Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
07:12AM	Q1 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
03:38AM	Glaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ... (GuruFocus.com)
May-01-24 11:53PM	GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:35PM	Glaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue Expectations (GuruFocus.com)
04:50PM	Glaukos: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces First Quarter 2024 Financial Results (Business Wire)
Apr-16-24 04:05PM	Glaukos Announces the Release of its 2023 Sustainability Report (Business Wire)
Apr-15-24 08:19AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Apr-12-24 09:22AM	Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally? (Zacks)
Apr-10-24 07:00AM	Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 (Business Wire)
Apr-08-24 10:41AM	Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock? (Zacks)
Apr-04-24 12:02PM	Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS (Zacks)
Apr-03-24 07:00AM	Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant) (Business Wire) +5.40%
Apr-01-24 07:00AM	Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting (Business Wire)
Mar-22-24 11:30AM	Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-13-24 07:56AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Feb-27-24 02:03AM	Glaukos Corp Director Mark Foley Sells 4,560 Shares (GuruFocus.com)
Feb-22-24 10:16AM	Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:58AM	Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
07:47AM	Q4 2023 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 05:20PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Glaukos Corp (GKOS) Reports Increased Sales but Widening Losses in Q4 and Full Year 2023 (GuruFocus.com)
04:17PM	Glaukos: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-15-24 02:04AM	Insider Sell: Glaukos Corp's President & COO Joseph Gilliam Sells 1,512 Shares (GuruFocus.com)
Feb-14-24 10:00AM	Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Feb-01-24 03:01PM	Glaukos Corp's President & COO Joseph Gilliam Sells 9,476 Shares (GuruFocus.com)
Jan-31-24 07:00AM	Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21 (Business Wire)
Jan-30-24 10:42AM	Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock? (Zacks)
Jan-18-24 07:57PM	Glaukos Corp Insider Sells Company Shares (GuruFocus.com)
Jan-16-24 07:41AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Jan-11-24 11:26AM	Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand (Zacks)
Jan-09-24 07:00AM	Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance (Business Wire) +5.55%
Dec-23-23 01:01AM	Glaukos Corp President & COO Joseph Gilliam Sells 25,000 Shares (GuruFocus.com)
Dec-21-23 01:31AM	Spotify, Salesforce shares gain following upgrades: 4 big analyst picks (Investing.com) +6.92%
Dec-20-23 07:00AM	Glaukos Announces Participation in the J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-23 01:28PM	Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment (Zacks)
Dec-18-23 09:49AM	Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock? (Zacks)
Dec-15-23 05:57AM	Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma (MedTech Dive) +7.58%
Dec-14-23 07:45AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks) +25.36%
07:00AM	Glaukos Announces FDA Approval of iDose TR (travoprost intracameral implant) (Business Wire)
Dec-03-23 10:30AM	Bearish Bets: 3 Stocks You Definitely Should Think About Shorting This Week (TheStreet.com)
Dec-01-23 11:31AM	Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report? (Zacks)
Nov-15-23 08:00AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Nov-07-23 07:00AM	Glaukos Announces Participation in Stifel Healthcare Conference (Business Wire)
Nov-02-23 06:17PM	Glaukos Corporation (NYSE:GKOS) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.58%
10:34AM	Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)
Nov-01-23 07:00PM	Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:07PM	Glaukos Corp (GKOS) Reports 10% Increase in Q3 2023 Net Sales (GuruFocus.com)
04:57PM	Glaukos: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-31-23 07:33AM	Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More (Zacks)
07:00AM	Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-11-23 07:00AM	Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023 (Business Wire)
Oct-05-23 07:53AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Sep-19-23 06:20AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? (Zacks)
Aug-23-23 07:00AM	Glaukos Announces Participation in Wells Fargo Healthcare Conference (Business Wire)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gilliam Joseph E	PRESIDENT & COO	Oct 30 '24	Option Exercise	69.30	2,275	157,658	104,444	Nov 01 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Oct 30 '24	Sale	138.97	2,275	316,157	102,169	Nov 01 05:30 PM
Gilliam Joseph E	Officer	Oct 30 '24	Proposed Sale	138.97	2,500	347,421		Oct 30 04:18 PM
Kliman Gilbert H	Director	Sep 09 '24	Option Exercise	32.00	3,000	96,000	35,336	Sep 11 07:49 PM
Kliman Gilbert H	Director	Sep 09 '24	Sale	130.67	3,000	392,000	32,336	Sep 11 07:49 PM
Kliman Gilbert H	Director	Sep 09 '24	Proposed Sale	130.67	3,000	392,000		Sep 09 03:03 PM
Gilliam Joseph E	PRESIDENT & COO	Aug 21 '24	Option Exercise	55.18	5,000	275,900	107,169	Aug 23 05:25 PM
Gilliam Joseph E	PRESIDENT & COO	Aug 21 '24	Sale	129.36	5,000	646,791	102,169	Aug 23 05:25 PM
Gilliam Joseph E	Officer	Aug 21 '24	Proposed Sale	129.36	5,000	646,803		Aug 21 04:19 PM
Stapley Marc	Director	Aug 15 '24	Option Exercise	32.00	6,250	200,000	40,326	Aug 19 05:15 PM
Stapley Marc	Director	Aug 15 '24	Sale	125.93	6,250	787,086	34,076	Aug 19 05:15 PM
Stapley Marc	Director	Aug 15 '24	Proposed Sale	125.93	6,250	787,074		Aug 15 05:12 PM
WEISNER AIMEE S	Director	Aug 08 '24	Option Exercise	32.00	25,000	800,000	55,119	Aug 12 05:05 PM
WEISNER AIMEE S	Director	Aug 08 '24	Sale	120.00	25,000	3,000,000	30,119	Aug 12 05:05 PM
WEISNER AIMEE S	Director	Aug 08 '24	Proposed Sale	120.00	25,000	3,000,000		Aug 08 12:15 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 05 '24	Option Exercise	69.30	2,250	155,925	104,095	Jul 09 05:10 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 05 '24	Sale	121.39	2,250	273,128	101,845	Jul 09 05:10 PM
Gilliam Joseph E	PRESIDENT & COO	Jun 03 '24	Option Exercise	55.18	2,500	137,950	104,345	Jun 05 07:35 PM
Gilliam Joseph E	PRESIDENT & COO	Jun 03 '24	Sale	113.50	2,500	283,751	101,845	Jun 05 07:35 PM
Kliman Gilbert H	Director	May 30 '24	Option Exercise	32.00	5,000	160,000	35,620	Jun 03 09:00 PM
Kliman Gilbert H	Director	May 30 '24	Sale	112.00	5,000	560,000	30,620	Jun 03 09:00 PM
Stapley Marc	Director	May 15 '24	Option Exercise	32.00	6,250	200,000	38,610	May 16 07:45 PM
Stapley Marc	Director	May 15 '24	Sale	112.80	6,250	704,993	32,360	May 16 07:45 PM
Gilliam Joseph E	PRESIDENT & COO	May 10 '24	Option Exercise	55.18	2,395	132,156	104,240	May 14 04:43 PM
Gilliam Joseph E	PRESIDENT & COO	May 10 '24	Sale	110.56	2,395	264,791	101,845	May 14 04:43 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 10 '24	Sale	110.51	353	39,011	51,647	May 14 04:41 PM
Gilliam Joseph E	PRESIDENT & COO	May 06 '24	Option Exercise	55.18	105	5,794	101,950	May 08 05:21 PM
Gilliam Joseph E	PRESIDENT & COO	May 06 '24	Sale	110.36	105	11,588	101,845	May 08 05:21 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 06 '24	Sale	110.26	90	9,923	52,000	May 08 05:08 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 02 '24	Sale	105.69	442	46,713	52,090	May 06 05:27 PM
Gilliam Joseph E	PRESIDENT & COO	May 02 '24	Option Exercise	69.30	2,059	142,689	103,904	May 06 05:23 PM
Gilliam Joseph E	PRESIDENT & COO	May 02 '24	Sale	105.52	2,059	217,263	101,845	May 06 05:23 PM
Hoffmeister David F	Director	Apr 10 '24	Option Exercise	7.28	10,000	72,750	15,767	Apr 12 07:49 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 08 '24	Option Exercise	41.69	59,801	2,493,104	161,646	Apr 10 08:20 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 08 '24	Sale	100.47	59,801	6,008,359	101,845	Apr 10 08:20 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	100.54	1,372	137,944	52,532	Apr 09 07:46 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 05 '24	Sale	96.63	262	25,316	53,904	Apr 09 07:46 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 05 '24	Option Exercise	55.18	2,457	135,577	104,302	Apr 09 07:40 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 05 '24	Sale	96.81	2,457	237,862	101,845	Apr 09 07:40 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 03 '24	Option Exercise	55.18	200	11,036	102,045	Apr 05 06:15 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 04 '24	Option Exercise	55.18	200	11,036	102,045	Apr 05 06:15 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 03 '24	Sale	96.61	200	19,322	101,845	Apr 05 06:15 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 04 '24	Sale	96.57	200	19,314	101,845	Apr 05 06:15 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 04 '24	Sale	95.33	434	41,371	54,166	Apr 05 06:13 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	94.62	316	29,900	54,600	Apr 05 06:13 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 02 '24	Sale	90.37	474	42,835	54,916	Apr 03 08:32 PM
Kliman Gilbert H	Director	Mar 07 '24	Option Exercise	32.00	5,000	160,000	35,620	Mar 08 05:12 PM
Kliman Gilbert H	Director	Mar 06 '24	Sale	85.34	8,347	712,307	0	Mar 08 05:12 PM
Kliman Gilbert H	Director	Mar 07 '24	Sale	88.25	5,000	441,250	30,620	Mar 08 05:12 PM
Stapley Marc	Director	Feb 29 '24	Option Exercise	32.00	6,250	200,000	38,610	Mar 04 08:09 PM
Stapley Marc	Director	Feb 29 '24	Sale	90.09	6,250	563,087	32,360	Mar 04 08:09 PM
Kliman Gilbert H	Director	Feb 27 '24	Sale	92.00	8,000	736,000	8,347	Feb 29 05:52 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 23 '24	Option Exercise	39.82	118,831	4,731,666	238,633	Feb 27 09:29 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 23 '24	Sale	92.14	140,245	12,922,002	98,388	Feb 27 09:29 PM
Foley Mark J	Director	Feb 23 '24	Option Exercise	7.28	10,000	72,750	37,780	Feb 26 07:01 PM
Foley Mark J	Director	Feb 23 '24	Sale	92.87	4,560	423,487	33,220	Feb 26 07:01 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 12 '24	Option Exercise	55.18	1,512	83,432	121,314	Feb 14 04:56 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 12 '24	Sale	96.80	1,512	146,362	119,802	Feb 14 04:56 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 08 '24	Option Exercise	39.10	5,000	195,500	124,802	Feb 12 06:41 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 09 '24	Option Exercise	55.18	631	34,819	120,433	Feb 12 06:41 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 08 '24	Sale	96.07	5,000	480,350	119,802	Feb 12 06:41 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 09 '24	Sale	96.70	631	61,018	119,802	Feb 12 06:41 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Feb 08 '24	Sale	95.78	550	52,682	54,035	Feb 09 06:33 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Feb 07 '24	Sale	95.00	33	3,135	54,585	Feb 09 06:33 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 29 '24	Option Exercise	39.10	9,476	370,512	129,278	Jan 31 05:35 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 29 '24	Sale	94.12	9,476	891,881	119,802	Jan 31 05:35 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 22 '24	Option Exercise	39.10	524	20,488	120,326	Jan 24 06:04 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 22 '24	Sale	94.01	524	49,261	119,802	Jan 24 06:04 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jan 18 '24	Sale	90.54	583	52,784	54,618	Jan 22 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 16 '24	Option Exercise	30.92	4,890	151,199	124,692	Jan 18 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 16 '24	Sale	89.17	4,890	436,041	119,802	Jan 18 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 12 '24	Option Exercise	30.92	110	3,401	119,912	Jan 16 04:59 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 12 '24	Sale	89.01	110	9,791	119,802	Jan 16 04:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 08 '24	Option Exercise	7.28	60,000	436,500	115,835	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 09 '24	Option Exercise	7.28	115	837	55,950	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 08 '24	Sale	82.55	60,000	4,952,706	55,835	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 09 '24	Sale	86.85	115	9,988	55,835	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 02 '24	Option Exercise	7.28	95,000	691,125	150,835	Jan 03 06:18 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 02 '24	Sale	77.20	95,000	7,334,253	55,835	Jan 03 06:18 PM
Gilliam Joseph E	PRESIDENT & COO	Dec 21 '23	Option Exercise	41.69	25,000	1,042,250	145,001	Dec 22 06:05 PM
Gilliam Joseph E	PRESIDENT & COO	Dec 21 '23	Sale	84.80	25,000	2,120,062	120,001	Dec 22 06:05 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Dec 21 '23	Sale	85.14	583	49,637	55,242	Dec 22 06:04 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 21 '23	Option Exercise	7.28	79,684	579,701	135,519	Dec 22 06:03 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 22 '23	Option Exercise	7.28	1	7	55,836	Dec 22 06:03 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 21 '23	Sale	85.21	79,684	6,789,874	55,835	Dec 22 06:03 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 22 '23	Sale	85.32	1	85	55,835	Dec 22 06:03 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Dec 15 '23	Sale	79.80	1,270	101,346	55,825	Dec 18 08:41 PM
Stapley Marc	Director	Dec 14 '23	Option Exercise	16.78	16,250	272,750	47,566	Dec 18 08:40 PM
Stapley Marc	Director	Dec 14 '23	Sale	75.93	16,250	1,233,875	31,316	Dec 18 08:40 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 15 '23	Option Exercise	7.28	60,000	436,500	115,835	Dec 18 08:39 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 14 '23	Option Exercise	7.28	30,000	218,250	85,835	Dec 18 08:39 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 15 '23	Sale	80.94	60,000	4,856,448	55,835	Dec 18 08:39 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 14 '23	Sale	75.91	30,000	2,277,357	55,835	Dec 18 08:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GKOS

Glaukos Corporation

Upgrade your FINVIZ experience